Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009
Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009
复制标题
DOI：
10.1016/j.ijantimicag.2011.02.004
复制
发表时间：
2011-06-01
影响因子：
10.8
通讯作者：
Chmelarova, Eva
中科院分区：
文献类型：
--
作者：
Dowzicky, Michael J.;Chmelarova, Eva
本研究报告了替格环素和包括利奈唑胺在内的对照抗菌剂对作为替环素评价和监测试验(TE.S.T.)一部分收集的金黄色葡萄球菌、肺炎链球菌、粪肠球菌和粪肠球菌的抗菌活性。在2004至2009年间。根据临床和实验室标准协会(CLSI)的指南，采用肉汤微量稀释法测定最低抑菌浓度(MIC)。根据CLSI标准进行药敏试验。对于替吉环素，使用了美国食品和药物管理局(FDA)批准的标准。41.3%(8249/19982)的金黄色葡萄球菌为耐甲氧西林金黄色葡萄球菌(MRSA)。所有耐甲氧西林金黄色葡萄球菌均对利奈唑胺敏感，对替格环素的敏感率为99.98%。粪肠球菌耐万古霉素的比例为2.3%(201/8576)，粪肠球菌耐万古霉素的比例为39.7%(1226/3088)。利奈唑胺和替加环素对肠球菌的MIC90值(90%的分离菌抑制)。分别为2 mg/L和
This study reports the antimicrobial activity of tigecycline and comparator antimicrobials, including linezolid, against Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus faecalis and Enterococcus faecium collected as part of the Tigecycline Evaluation and Surveillance Trial (T. E. S. T.) between 2004 and 2009. Minimum inhibitory concentrations (MICs) were determined using broth microdilution methodology according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI). Antimicrobial susceptibility was determined according to CLSI criteria. For tigecycline, the US Food and Drug Administration (FDA)-approved criteria were used. Overall, 41.3% (8249/19 982) of S. aureus collected were meticillin-resistant S. aureus (MRSA). All MRSA were susceptible to linezolid and 99.98% were susceptible to tigecycline. A total of 2.3% of E. faecalis (201/8576) and 39.7% of E. faecium (1226/3088) were vancomycin-resistant. Linezolid and tigecycline MIC90 values (MIC at which 90% of isolates inhibited) against the Enterococcus spp. were 2 mg/L and